Related Experiment Videos
Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450
Abstract:
A metabolite of thalidomide generated by hepatic microsomes inhibited the attachment of tumor cells to concanavalin A-coated polyethylene. Evidence that metabolite formation is mediated by microsomal cytochrome P-450 is presented. Microsomes incubated with thalidomide underwent a type I spectral shift. Metabolite formation was reduced or eliminated by carbon monoxide, SKF-525A, metyrapone, and N-octylamine. Superoxide dismutase treatment had no effect. Metabolite formation required microsomes and NADPH and was dependent on the length of 37 degrees C incubation. The metabolite could be isolated by successive hexane and chloroform extractions. It is likely the inhibitory thalidomide metabolite was generated by a minor cytochrome P-450 species. Whether this thalidomide metabolite is involved in the drug's teratogenic activity remains to be shown.
Insights
A thalidomide metabolite produced by liver enzymes inhibits tumor cell attachment. This metabolite is likely formed by cytochrome P-450, a key enzyme in drug metabolism.
Area of Science:
- Biochemistry
- Pharmacology
- Toxicology
Background:
- Thalidomide is a drug with known teratogenic effects.
- Hepatic microsomes are involved in drug metabolism.
- Cytochrome P-450 enzymes play a crucial role in metabolizing xenobiotics.
Purpose of the Study:
- To investigate the metabolic activation of thalidomide by hepatic microsomes.
- To identify the enzymatic pathway responsible for thalidomide metabolite formation.
- To characterize the biological activity of the thalidomide metabolite.
Main Methods:
- Incubation of thalidomide with hepatic microsomes.
- Spectroscopic analysis (Type I spectral shift) to detect cytochrome P-450 interaction.
- Enzyme inhibition studies using specific cytochrome P-450 inhibitors (CO, SKF-525A, metyrapone, N-octylamine).
- Assessment of tumor cell attachment to concanavalin A-coated surfaces.
Main Results:
- A thalidomide metabolite was formed by hepatic microsomes.
- The metabolite inhibited the attachment of tumor cells to concanavalin A.
- Metabolite formation was dependent on NADPH and microsomes, indicating enzymatic activity.
- Evidence suggests cytochrome P-450 mediates metabolite formation, indicated by spectral shifts and inhibition studies.
- Superoxide dismutase did not affect metabolite formation.
Conclusions:
- Thalidomide is metabolized by hepatic microsomes, likely via a cytochrome P-450-dependent pathway.
- The resulting metabolite exhibits anti-adhesive properties against tumor cells.
- Further research is needed to determine if this metabolite contributes to thalidomide's teratogenicity.